The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma
Abstract
:1. Introduction
2. Common Genetic Alterations Predisposing to PM
2.1. Germline Mutations
2.2. Somatic Mutations
2.3. BAP1
2.4. CDKN2A
2.5. MTAP
2.6. TP53
2.7. NF2
2.8. LATS2
3. Potential Epigenetic Targets
4. Conclusions and Future Perspectives
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Attanoos, R.; Gibbs, A. Pathology of Malignant Mesothelioma. Histopathology 1997, 30, 403–418. [Google Scholar] [CrossRef] [PubMed]
- Keshava, H.B.; Tang, A.; Siddiqui, H.U.; Raja, S.; Raymond, D.P.; Bribriesco, A.; Stevenson, J.; Murthy, S.C.; Ahmad, U. Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA. World J. Surg. 2019, 43, 3239–3247. [Google Scholar] [CrossRef] [PubMed]
- Verma, V.; Ahern, C.A.; Berlind, C.G.; Lindsay, W.D.; Shabason, J.; Sharma, S.; Culligan, M.J.; Grover, S.; Friedberg, J.S.; Simone, C.B. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival. Clin. Lung Cancer 2018, 19, e901–e912. [Google Scholar] [CrossRef]
- Paajanen, J.; Laaksonen, S.; Kettunen, E.; Ilonen, I.; Vehmas, T.; Salo, J.; Räsänen, J.; Sutinen, E.; Ollila, H.; Mäyränpää, M.I.; et al. Histopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survival. Hum. Pathol. 2020, 98, 110–119. [Google Scholar] [CrossRef] [PubMed]
- Paajanen, J.; Laaksonen, S.; Ilonen, I.; Vehmas, T.; Mäyränpää, M.I.; Sutinen, E.; Kettunen, E.; Salo, J.A.; Räsänen, J.; Wolff, H.; et al. Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses. Clin. Lung Cancer 2020, 21, e633–e639. [Google Scholar] [CrossRef]
- Brcic, L.; Kern, I. Clinical significance of histologic subtyping of malignant pleural mesothelioma. Transl. Lung Cancer Res. 2020, 9, 924–933. [Google Scholar] [CrossRef]
- Kindler, H.L.; Ismaila, N.; Armato, S.G.; Bueno, R.; Hesdorffer, M.; Jahan, T.; Jones, C.M.; Miettinen, M.; Pass, H.; Rimner, A.; et al. Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline. J. Clin. Oncol. 2018, 36, 1343–1373. [Google Scholar] [CrossRef]
- Lapidot, M.; Gill, R.R.; Mazzola, E.; Freyaldenhoven, S.; Swanson, S.J.; Jaklitsch, M.T.; Sugarbaker, D.J.; Bueno, R. Pleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma. Ann. Surg. 2020, 275, 1212–1220. [Google Scholar] [CrossRef]
- Nicolini, F.; Bocchini, M.; Bronte, G.; Delmonte, A.; Guidoboni, M.; Crinò, L.; Mazza, M. Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future. Front. Oncol. 2020, 9, 1519. [Google Scholar] [CrossRef]
- Vogelzang, N.J.; Rusthoven, J.J.; Symanowski, J.; Denham, C.; Kaukel, E.; Ruffie, P.; Gatzemeier, U.; Boyer, M.; Emri, S.; Manegold, C.; et al. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma. J. Clin. Oncol. 2003, 21, 2636–2644. [Google Scholar] [CrossRef]
- Zalcman, G.; Mazieres, J.; Margery, J.; Greillier, L.; Audigier-Valette, C.; Moro-Sibilot, D.; Molinier, O.; Corre, R.; Monnet, I.; Gounant, V.; et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet 2016, 387, 1405–1414. [Google Scholar] [CrossRef]
- Baas, P.; Scherpereel, A.; Nowak, A.K.; Fujimoto, N.; Peters, S.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Jahan, T.; Antonia, S.; et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet 2021, 397, 375–386. [Google Scholar] [CrossRef]
- Bueno, R.; Stawiski, E.W.; Goldstein, L.D.; Durinck, S.; De Rienzo, A.; Modrusan, Z.; Gnad, F.; Nguyen, T.T.; Jaiswal, B.S.; Chirieac, L.R.; et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 2016, 48, 407–416. [Google Scholar] [CrossRef] [PubMed]
- Hmeljak, J.; Sanchez-Vega, F.; Hoadley, K.A.; Shih, J.; Stewart, C.; Heiman, D.; Tarpey, P.; Danilova, L.; Drill, E.; Gibb, E.A.; et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018, 8, 1549–1565. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Reynies, A.; Jaurand, M.C.; Renier, A.; Couchy, G.; Hysi, I.; Elarouci, N.; Galateau-Sallé, F.; Copin, M.C.; Hofman, P.; Cazes, A.; et al. Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin. Cancer Res. 2014, 20, 1323–1334. [Google Scholar] [CrossRef] [Green Version]
- Severson, D.T.; De Rienzo, A.; Bueno, R. Mesothelioma in the age of “Omics”: Before and after The Cancer Genome Atlas. J. Thorac. Cardiovasc. Surg. 2020, 160, 1078–1083.e2. [Google Scholar] [CrossRef]
- Szlosarek, P.W.; Steele, J.P.; Nolan, L.; Gilligan, D.; Taylor, P.; Spicer, J.; Lind, M.; Mitra, S.; Shamash, J.; Phillips, M.M.; et al. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA Oncol. 2017, 3, 58–66. [Google Scholar] [CrossRef]
- Fennell, D.A.; King, A.; Mohammed, S.; Branson, A.; Brookes, C.; Darlison, L.; Dawson, A.G.; Gaba, A.; Hutka, M.; Morgan, B.; et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): An open-label, single-arm, phase 2a clinical trial. Lancet. Respir. Med. 2021, 9, 593–600. [Google Scholar] [CrossRef]
- Fennell, D.A.; King, A.; Mohammed, S.; Greystoke, A.; Anthony, S.; Poile, C.; Nusrat, N.; Scotland, M.; Bhundia, V.; Branson, A.; et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): A single-arm, open-label, phase 2 trial. Lancet Oncol. 2022, 23, 374–381. [Google Scholar] [CrossRef]
- Fennell, D.A.; Baas, P.; Taylor, P.; Nowak, A.K.; Gilligan, D.; Nakano, T.; Pachter, J.A.; Weaver, D.T.; Scherpereel, A.; Pavlakis, N.; et al. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study. J. Clin. Oncol. 2019, 37, 790–798. [Google Scholar] [CrossRef]
- Zauderer, M.G.; Szlosarek, P.W.; Le Moulec, S.; Popat, S.; Taylor, P.; Planchard, D.; Scherpereel, A.; Koczywas, M.; Forster, M.; Cameron, R.B.; et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study. Lancet Oncol. 2022, 23, 758–767. [Google Scholar] [CrossRef]
- Szlosarek, P.W.; Phillips, M.M.; Pavlyk, I.; Steele, J.; Shamash, J.; Spicer, J.; Kumar, S.; Pacey, S.; Feng, X.; Johnston, A.; et al. Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms. JTO Clin. Res. Rep. 2020, 1, 100093. [Google Scholar] [CrossRef] [PubMed]
- Kindler, H.L.; Burris, H.A., 3rd; Sandler, A.B.; Oliff, I.A. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Investig. New Drugs 2009, 27, 75–81. [Google Scholar] [CrossRef]
- Sekido, Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 2013, 34, 1413–1419. [Google Scholar] [CrossRef] [PubMed]
- Testa, J.R.; Cheung, M.; Pei, J.; Below, J.E.; Tan, Y.; Sementino, E.; Cox, N.J.; Dogan, A.U.; Pass, H.I.; Trusa, S.; et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 2011, 43, 1022–1026. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Napolitano, A.; Pellegrini, L.; Dey, A.; Larson, D.; Tanji, M.; Flores, E.G.; Kendrick, B.; Lapid, D.; Powers, A.; Kanodia, S.; et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 2016, 35, 1996–2002. [Google Scholar] [CrossRef]
- Carbone, M.; Ferris, L.K.; Baumann, F.; Napolitano, A.; Lum, C.A.; Flores, E.G.; Gaudino, G.; Powers, A.; Bryant-Greenwood, P.; Krausz, T.; et al. BAP1 cancer syndrome: Malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl. Med. 2012, 10, 179. [Google Scholar] [CrossRef] [Green Version]
- Carbone, M.; Pass, H.I.; Ak, G.; Alexander, H.R.; Baas, P.; Baumann, F.; Blakely, A.M.; Bueno, R.; Bzura, A.; Cardillo, G.; et al. Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations. J. Thorac. Oncol. 2022, 17, 873–889. [Google Scholar] [CrossRef]
- Chau, C.; van Doorn, R.; van Poppelen, N.M.; van der Stoep, N.; Mensenkamp, A.R.; Sijmons, R.H.; van Paassen, B.W.; van den Ouweland, A.M.W.; Naus, N.C.; van der Hout, A.H.; et al. Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines. Cancers 2019, 11, 1114. [Google Scholar] [CrossRef] [Green Version]
- Pastorino, S.; Yoshikawa, Y.; Pass, H.I.; Emi, M.; Nasu, M.; Pagano, I.; Takinishi, Y.; Yamamoto, R.; Minaai, M.; Hashimoto-Tamaoki, T.; et al. A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. J. Clin. Oncol. 2018, 36, 3485–3494. [Google Scholar] [CrossRef]
- Baumann, F.; Flores, E.; Napolitano, A.; Kanodia, S.; Taioli, E.; Pass, H.; Yang, H.; Carbone, M. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 2015, 36, 76–81. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zauderer, M.G.; Bott, M.; McMillan, R.; Sima, C.S.; Rusch, V.; Krug, L.M.; Ladanyi, M. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J. Thorac. Oncol. 2013, 8, 1430–1433. [Google Scholar] [CrossRef] [Green Version]
- Carbone, M.; Kanodia, S.; Chao, A.; Miller, A.; Wali, A.; Weissman, D.; Adjei, A.; Baumann, F.; Boffetta, P.; Buck, B.; et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J. Thorac. Oncol. 2016, 11, 1246–1262. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Panou, V.; Gadiraju, M.; Wolin, A.; Weipert, C.M.; Skarda, E.; Husain, A.N.; Patel, J.D.; Rose, B.; Zhang, S.R.; Weatherly, M.; et al. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J. Clin. Oncol. 2018, 36, 2863–2871. [Google Scholar] [CrossRef] [PubMed]
- Guo, G.; Chmielecki, J.; Goparaju, C.; Heguy, A.; Dolgalev, I.; Carbone, M.; Seepo, S.; Meyerson, M.; Pass, H.I. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015, 75, 264–269. [Google Scholar] [CrossRef] [Green Version]
- Zhang, M.; Luo, J.-L.; Sun, Q.; Harber, J.; Dawson, A.G.; Nakas, A.; Busacca, S.; Sharkey, A.J.; Waller, D.; Sheaff, M.T.; et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat. Commun. 2021, 12, 1751. [Google Scholar] [CrossRef]
- Jean, D.; Daubriac, J.; Le Pimpec-Barthes, F.; Galateau-Salle, F.; Jaurand, M.C. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch. Pathol. Lab. Med. 2012, 136, 277–293. [Google Scholar] [CrossRef] [Green Version]
- Mansfield, A.S.; Peikert, T.; Smadbeck, J.B.; Udell, J.B.M.; Garcia-Rivera, E.; Elsbernd, L.; Erskine, C.L.; Van Keulen, V.P.; Kosari, F.; Murphy, S.J.; et al. Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. J. Thorac. Oncol. 2019, 14, 276–287. [Google Scholar] [CrossRef] [Green Version]
- Vandermeers, F.; Neelature Sriramareddy, S.; Costa, C.; Hubaux, R.; Cosse, J.-P.; Willems, L. The role of epigenetics in malignant pleural mesothelioma. Lung Cancer 2013, 81, 311–318. [Google Scholar] [CrossRef]
- Bueno, R.; De Rienzo, A.; Dong, L.; Gordon, G.J.; Hercus, C.F.; Richards, W.G.; Jensen, R.V.; Anwar, A.; Maulik, G.; Chirieac, L.R.; et al. Second Generation Sequencing of the Mesothelioma Tumor Genome. PLoS ONE 2010, 5, e10612. [Google Scholar] [CrossRef]
- Kang, H.C.; Kim, H.K.; Lee, S.; Mendez, P.; Kim, J.W.; Woodard, G.; Yoon, J.; Jen, K.; Fang, L.T.; Jones, K.; et al. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget 2016, 7, 8321–8331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Creaney, J.; Patch, A.-M.; Addala, V.; Sneddon, S.A.; Nones, K.; Dick, I.M.; Lee, Y.C.G.; Newell, F.; Rouse, E.J.; Naeini, M.M.; et al. Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. Genome Med. 2022, 14, 58. [Google Scholar] [CrossRef] [PubMed]
- Xu, D.; Yang, H.; Schmid, R.; Peng, R.-W. Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight. Front. Oncol. 2020, 10, 579464. [Google Scholar] [CrossRef] [PubMed]
- Nasu, M.; Emi, M.; Pastorino, S.; Tanji, M.; Powers, A.; Luk, H.; Baumann, F.; Zhang, Y.A.; Gazdar, A.; Kanodia, S.; et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J. Thorac. Oncol. 2015, 10, 565–576. [Google Scholar] [CrossRef] [Green Version]
- De Rienzo, A.; Chirieac, L.R.; Hung, Y.P.; Severson, D.T.; Freyaldenhoven, S.; Gustafson, C.E.; Dao, N.T.; Meyerovitz, C.V.; Oster, M.E.; Jensen, R.V.; et al. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma. J. Pathol. 2021, 253, 68–79. [Google Scholar] [CrossRef] [PubMed]
- Yu, H.; Pak, H.; Hammond-Martel, I.; Ghram, M.; Rodrigue, A.; Daou, S.; Barbour, H.; Corbeil, L.; Hébert, J.; Drobetsky, E.; et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc. Natl. Acad. Sci. USA 2014, 111, 285–290. [Google Scholar] [CrossRef] [Green Version]
- Lord, C.J.; Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017, 355, 1152–1158. [Google Scholar] [CrossRef]
- Srinivasan, G.; Sidhu, G.S.; Williamson, E.A.; Jaiswal, A.S.; Najmunnisa, N.; Wilcoxen, K.; Jones, D.; George, T.J.J.; Hromas, R. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother. Pharmacol. 2017, 80, 861–867. [Google Scholar] [CrossRef] [Green Version]
- Rathkey, D.; Khanal, M.; Murai, J.; Zhang, J.; Sengupta, M.; Jiang, Q.; Morrow, B.; Evans, C.N.; Chari, R.; Fetsch, P.; et al. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. J. Thorac. Oncol. 2020, 15, 843–859. [Google Scholar] [CrossRef]
- Ghafoor, A.; Mian, I.; Wagner, C.; Mallory, Y.; Agra, M.G.; Morrow, B.; Wei, J.S.; Khan, J.; Thomas, A.; Sengupta, M.; et al. Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene. JTO Clin. Res. Rep. 2021, 2, 100231. [Google Scholar] [CrossRef]
- LaFave, L.M.; Béguelin, W.; Koche, R.; Teater, M.; Spitzer, B.; Chramiec, A.; Papalexi, E.; Keller, M.D.; Hricik, T.; Konstantinoff, K.; et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 2015, 21, 1344–1349. [Google Scholar] [CrossRef] [PubMed]
- Grard, M.; Chatelain, C.; Delaunay, T.; Pons-tostivint, E. Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy. Front. Oncol. 2021, 11, 695770. [Google Scholar] [CrossRef] [PubMed]
- Altomare, D.A.; Menges, C.W.; Xu, J.; Pei, J.; Zhang, L.; Tadevosyan, A.; Neumann-Domer, E.; Liu, Z.; Carbone, M.; Chudoba, I.; et al. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS ONE 2011, 6, e18828. [Google Scholar] [CrossRef] [PubMed]
- Marshall, K.; Jackson, S.; Jones, J.; Holme, J.; Lyons, J.; Barrett, E.; Taylor, P.; Bishop, P.; Hodgson, C.; Green, M.; et al. Homozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre. Lung Cancer 2020, 150, 195–200. [Google Scholar] [CrossRef]
- Illei, P.B.; Rusch, V.W.; Zakowski, M.F.; Ladanyi, M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin. cancer Res. Off. J. Am. Assoc. Cancer Res. 2003, 9, 2108–2113. [Google Scholar]
- Wong, L.; Zhou, J.; Anderson, D.; Kratzke, R.A. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002, 38, 131–136. [Google Scholar] [CrossRef]
- Pezzuto, F.; Lunardi, F.; Vedovelli, L.; Fortarezza, F.; Urso, L.; Grosso, F.; Ceresoli, G.L.; Kern, I.; Vlacic, G.; Faccioli, E.; et al. P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. Front. Oncol. 2021, 11, 653497. [Google Scholar] [CrossRef]
- Canon, J.; Osgood, T.; Olson, S.H.; Saiki, A.Y.; Robertson, R.; Yu, D.; Eksterowicz, J.; Ye, Q.; Jin, L.; Chen, A.; et al. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Mol. Cancer Ther. 2015, 14, 649–658. [Google Scholar] [CrossRef] [Green Version]
- Gluck, W.L.; Gounder, M.M.; Frank, R.; Eskens, F.; Blay, J.Y.; Cassier, P.A.; Soria, J.-C.; Chawla, S.; de Weger, V.; Wagner, A.J.; et al. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investig. New Drugs 2020, 38, 831–843. [Google Scholar] [CrossRef] [Green Version]
- Bonelli, M.; Terenziani, R.; Zoppi, S.; Fumarola, C.; La Monica, S.; Cretella, D.; Alfieri, R.; Cavazzoni, A.; Digiacomo, G.; Galetti, M.; et al. Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells. Int. J. Mol. Sci. 2020, 21, 5165. [Google Scholar] [CrossRef]
- Vilgelm, A.E.; Saleh, N.; Shattuck-Brandt, R.; Riemenschneider, K.; Slesur, L.; Chen, S.-C.; Johnson, C.A.; Yang, J.; Blevins, A.; Yan, C.; et al. MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. Sci. Transl. Med. 2019, 11, eaav7171. [Google Scholar] [CrossRef] [PubMed]
- Jang, H.; Truong, C.Y.; Lo, E.M.; Holmes, H.M.; Ramos, D.; Ramineni, M.; Lee, J.; Wang, D.Y.; Pietropaolo, M.; Ripley, R.T.; et al. Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma. Ann. Thorac. Surg. 2022, 114, 1842–1852. [Google Scholar] [CrossRef] [PubMed]
- Li, W.; Su, D.; Mizobuchi, H.; Martin, D.S.; Gu, B.; Gorlick, R.; Cole, P.; Bertino, J.R. Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. Oncol. Res. 2004, 14, 373–379. [Google Scholar] [CrossRef]
- Batova, A.; Diccianni, M.B.; Omura-Minamisawa, M.; Yu, J.; Carrera, C.J.; Bridgeman, L.J.; Kung, F.H.; Pullen, J.; Amylon, M.D.; Yu, A.L. Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. Cancer Res. 1999, 59, 1492–1497. [Google Scholar]
- Kalev, P.; Hyer, M.L.; Gross, S.; Konteatis, Z.; Chen, C.-C.; Fletcher, M.; Lein, M.; Aguado-Fraile, E.; Frank, V.; Barnett, A.; et al. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage. Cancer Cell 2021, 39, 209–224.e11. [Google Scholar] [CrossRef] [PubMed]
- Ozaki, T.; Nakagawara, A. Role of p53 in Cell Death and Human Cancers. Cancers 2011, 3, 994–1013. [Google Scholar] [CrossRef] [Green Version]
- Xu, D.; Liang, S.-Q.; Yang, H.; Bruggmann, R.; Berezowska, S.; Yang, Z.; Marti, T.M.; Hall, S.R.R.; Gao, Y.; Kocher, G.J.; et al. CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. Mol. Cancer Ther. 2020, 19, 661–672. [Google Scholar] [CrossRef] [Green Version]
- Chapel, D.B.; Hornick, J.L.; Barlow, J.; Bueno, R.; Sholl, L.M. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma. Mod. Pathol. 2022, 35, 1383–1397. [Google Scholar] [CrossRef]
- Krug, L.M.; Wozniak, A.J.; Kindler, H.L.; Feld, R.; Koczywas, M.; Morero, J.L.; Rodriguez, C.P.; Ross, H.J.; Bauman, J.E.; Orlov, S.V.; et al. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer 2014, 85, 429–434. [Google Scholar] [CrossRef]
- Di Marzo, D.; Forte, I.M.; Indovina, P.; Di Gennaro, E.; Rizzo, V.; Giorgi, F.; Mattioli, E.; Iannuzzi, C.A.; Budillon, A.; Giordano, A.; et al. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle 2014, 13, 652–665. [Google Scholar] [CrossRef] [Green Version]
- Evans, D.G.R. Neurofibromatosis type 2 (NF2): A clinical and molecular review. Orphanet J. Rare Dis. 2009, 4, 16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miyanaga, A.; Masuda, M.; Tsuta, K.; Kawasaki, K.; Nakamura, Y.; Sakuma, T.; Asamura, H.; Gemma, A.; Yamada, T. Hippo pathway gene mutations in malignant mesothelioma: Revealed by RNA and targeted exon sequencing. J. Thorac. Oncol. 2015, 10, 844–851. [Google Scholar] [CrossRef] [PubMed]
- Sato, T.; Sekido, Y. NF2/merlin inactivation and potential therapeutic targets in mesothelioma. Int. J. Mol. Sci. 2018, 19, 988. [Google Scholar] [CrossRef] [Green Version]
- Zhang, W.-Q.; Dai, Y.-Y.; Hsu, P.-C.; Wang, H.; Cheng, L.; Yang, Y.-L.; Wang, Y.-C.; Xu, Z.-D.; Liu, S.; Chan, G.; et al. Targeting YAP in malignant pleural mesothelioma. J. Cell. Mol. Med. 2017, 21, 2663–2676. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Woodard, G.A.; Yang, Y.; You, L.; Jablons, D.M. Drug development against the hippo pathway in mesothelioma. Transl. Lung Cancer Res. 2017, 6, 335–342. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oien, D.B.; Sarkar Bhattacharya, S.; Chien, J.; Molina, J.; Shridhar, V. Quinacrine Has Preferential Anticancer Effects on Mesothelioma Cells With Inactivating NF2 Mutations. Front. Pharmacol. 2021, 12, 750352. [Google Scholar] [CrossRef]
- Shapiro, I.M.; Kolev, V.N.; Vidal, C.M.; Kadariya, Y.; Ring, J.E.; Wright, Q.; Weaver, D.T.; Menges, C.; Padval, M.; McClatchey, A.I.; et al. Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship. Sci. Transl. Med. 2014, 6, ra68–ra237. [Google Scholar] [CrossRef] [Green Version]
- Poulikakos, P.I.; Xiao, G.-H.; Gallagher, R.; Jablonski, S.; Jhanwar, S.C.; Testa, J.R. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006, 25, 5960–5968. [Google Scholar] [CrossRef] [Green Version]
- Soria, J.C.; Gan, H.K.; Blagden, S.P.; Plummer, R.; Arkenau, H.T.; Ranson, M.; Evans, T.R.J.; Zalcman, G.; Bahleda, R.; Hollebecque, A.; et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann. Oncol. 2016, 27, 2268–2274. [Google Scholar] [CrossRef]
- Bueno, R.; Gill, R.R.; Lizotte, P.H.; Sprott, K.; Jackman, D.M.; Barlow, J.; Sharma, S.; Yeap, B.Y.; Chirieac, L.R.; Lebenthal, A.; et al. Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM). J. Clin. Oncol. 2017, 35, 8555. [Google Scholar] [CrossRef]
- López-Lago, M.A.; Okada, T.; Murillo, M.M.; Socci, N.; Giancotti, F.G. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol. Cell. Biol. 2009, 29, 4235–4249. [Google Scholar] [CrossRef] [Green Version]
- Li, N.; Lu, X.Y.; Shi, W.Y.; Mao, F.J.; Yang, X.Y.; Luo, Y.B.; Li, W. Combined mTOR/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 5874–5883. [Google Scholar] [CrossRef] [PubMed]
- Ou, S.-H.I.; Moon, J.; Garland, L.L.; Mack, P.C.; Testa, J.R.; Tsao, A.S.; Wozniak, A.J.; Gandara, D.R. SWOG S0722: Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM). J. Thorac. Oncol. 2015, 10, 387–391. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rodrik-Outmezguine, V.S.; Okaniwa, M.; Yao, Z.; Novotny, C.J.; McWhirter, C.; Banaji, A.; Won, H.; Wong, W.; Berger, M.; de Stanchina, E.; et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 2016, 534, 272–276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Furth, N.; Aylon, Y. The LATS1 and LATS2 tumor suppressors: Beyond the Hippo pathway. Cell Death Differ. 2017, 24, 1488–1501. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Quetel, L.; Meiller, C.; Assié, J.B.; Blum, Y.; Imbeaud, S.; Montagne, F.; Tranchant, R.; de Wolf, J.; Caruso, S.; Copin, M.C.; et al. Genetic alterations of malignant pleural mesothelioma: Association with tumor heterogeneity and overall survival. Mol. Oncol. 2020, 14, 1207–1223. [Google Scholar] [CrossRef] [Green Version]
- Mizuno, T.; Murakami, H.; Fujii, M.; Ishiguro, F.; Tanaka, I.; Kondo, Y.; Akatsuka, S.; Toyokuni, S.; Yokoi, K.; Osada, H.; et al. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene 2012, 31, 5117–5122. [Google Scholar] [CrossRef] [Green Version]
- Scherpereel, A.; Berghmans, T.; Lafitte, J.J.; Colinet, B.; Richez, M.; Bonduelle, Y.; Meert, A.P.; Dhalluin, X.; Leclercq, N.; Paesmans, M.; et al. Valproate–doxorubicin: Promising therapy for progressing mesothelioma. A phase II study. Eur. Respir. J. 2011, 37, 129 LP-135. [Google Scholar] [CrossRef] [Green Version]
- Krug, L.M.; Kindler, H.L.; Calvert, H.; Manegold, C.; Tsao, A.S.; Fennell, D.; Öhman, R.; Plummer, R.; Eberhardt, W.E.E.; Fukuoka, K.; et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): A phase 3, double-blind, randomised, placebo-controlled trial. Lancet. Oncol. 2015, 16, 447–456. [Google Scholar] [CrossRef]
- Reardon, E.S.; Shukla, V.; Xi, S.; Gara, S.K.; Liu, Y.; Straughan, D.; Zhang, M.; Hong, J.A.; Payabyab, E.C.; Kumari, A.; et al. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma. J. Thorac. Oncol. 2021, 16, 89–103. [Google Scholar] [CrossRef]
- Ashraf, W.; Ibrahim, A.; Alhosin, M.; Zaayter, L.; Ouararhni, K.; Papin, C.; Ahmad, T.; Hamiche, A.; Mély, Y.; Bronner, C.; et al. The epigenetic integrator UHRF1: On the road to become a universal biomarker for cancer. Oncotarget 2017, 8, 51946–51962. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zou, S.; Wang, X.; Liu, P.; Ke, C.; Xu, S. Arginine metabolism and deprivation in cancer therapy. Biomed. Pharmacother. 2019, 118, 109210. [Google Scholar] [CrossRef] [PubMed]
- Allen, M.D.; Luong, P.; Hudson, C.; Leyton, J.; Delage, B.; Ghazaly, E.; Cutts, R.; Yuan, M.; Syed, N.; Lo Nigro, C.; et al. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res. 2014, 74, 896–907. [Google Scholar] [CrossRef] [Green Version]
- Blum, Y.; Meiller, C.; Quetel, L.; Elarouci, N.; Ayadi, M.; Tashtanbaeva, D.; Armenoult, L.; Montagne, F.; Tranchant, R.; Renier, A.; et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat. Commun. 2019, 10, 1333. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Slyper, M.; Porter, C.B.M.; Ashenberg, O.; Waldman, J.; Drokhlyansky, E.; Wakiro, I.; Smillie, C.; Smith-Rosario, G.; Wu, J.; Dionne, D.; et al. A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat. Med. 2020, 26, 792–802. [Google Scholar] [CrossRef] [PubMed]
Gene Name (Symbol) | Chromosomal Region | Mutation Frequency, (N = 202) | Potential Therapeutic Targets |
---|---|---|---|
BRCA1 associated protein 1 (BAP1) | 3p21.1 | 35 (17%) | EZH2; PARP |
Cyclin-dependent kinase inhibitor 2A (CDKN2A) | 9p21.3 | NA | MDM2; p53; CDK4/6 |
Methylthioadenosine phosphorylase (MTAP) | 9p21.3 | NA | Adenylosuccinate synthetase; MAT2A; PRMT |
Tumor protein P53 (TP53) | 17p13.1 | 14 (7%) | G2-checkpoint; MDM2; p53 |
Neurofibromatosis 2 (NF2) | 22q12.2 | 32 (16%) | YAP-TEAD; FAK; mTOR and PI3K |
The large tumor suppressor kinase 2 (LATS2) | 13q12.11 | 1 (1%) | YAP-TEAD |
SET domain containing 2 histone lysine methyltransferase (SETD2) | 3p21.31 | 17 (8%) | Histone deacetylase; DNA methyltransferase |
SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) | 1q21 | 3 (1%) | Histone deacetylase; DNA methyltransferase |
Author [Ref] | Design | Stratification | Treatment | Control Group | Subjects | PM 1 Patients | ORR 2, % | Median PFS 3, Months | Median OS 4, Months |
---|---|---|---|---|---|---|---|---|---|
Kindler [23] | Single-arm | MTAP | L-alanosine | None | Solid tumors | 16 | 0 | 2.1 | 5.5 |
Fennell [19] | Single-arm | P16ink4A | Abemaciclib | None | Pretreated advanced PM | 26 | 12 | 4.2 | 7.1 |
Fennell [18] | Single-arm | BAP1/BRCA1 | Rucaparib | None | Pretreated advanced PM | 25 | 12 | 4.1 | 9.5 |
Zauderer [21] | Single-arm | BAP1 | Tazemetostat | None | Pretreated advanced PM | 68 | 3 | 4.1 | 8.3 |
Fennell [20] | Randomized, double-blind | Merlin | Defactinib | Placebo | Pretreated Advanced PM | 344 | 4.0 vs. 2.9 | 4.1 vs. 4.0 | 12.7 vs. 13.6 |
Szlosarek [17] | Randomized | ASS1 | ADI-PEG20 | BSC 5 | Advanced PM | 68 | 0 | 3.2 vs. 2.0 | 11.5 vs. 11.1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Paajanen, J.; Bueno, R.; De Rienzo, A. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma. Int. J. Mol. Sci. 2022, 23, 13422. https://doi.org/10.3390/ijms232113422
Paajanen J, Bueno R, De Rienzo A. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma. International Journal of Molecular Sciences. 2022; 23(21):13422. https://doi.org/10.3390/ijms232113422
Chicago/Turabian StylePaajanen, Juuso, Raphael Bueno, and Assunta De Rienzo. 2022. "The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma" International Journal of Molecular Sciences 23, no. 21: 13422. https://doi.org/10.3390/ijms232113422